Nuevocor raises funding for LMNA therapy trial
Nuevocor has raised USD 45 million in a Series B funding round co-led by Kurma Partners and Angelini Ventures, with participation from EDBI, ClavystBio, Boehringer Ingelheim Venture Fund, Highlight Capital, and Seeds Capital. The funding will support clinical development of NVC-001, a gene therapy for LMNA-related cardiomyopathy, with trials set to begin in 2026 across sites in the US and Europe.